Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer

Oncogene. 2021 Oct;40(41):5984-5992. doi: 10.1038/s41388-021-01972-6. Epub 2021 Aug 12.

Abstract

PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the adenomatous polyposis coli (APC) gene lead to colonic epithelial cell resistance to CD8+ T cell cytotoxicity by induction of PD-L1 expression. Mechanistically, this occurs as a result of the β-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway but also pave the way for developing β-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenomatous Polyposis Coli Protein / genetics*
  • Adenomatous Polyposis Coli Protein / immunology
  • Animals
  • B7-H1 Antigen / biosynthesis
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / immunology*
  • CD8-Positive T-Lymphocytes / immunology
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / immunology*
  • Gene Knockdown Techniques
  • HEK293 Cells
  • HT29 Cells
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Tumor Escape / genetics

Substances

  • APC protein, human
  • Adenomatous Polyposis Coli Protein
  • B7-H1 Antigen
  • CD274 protein, human
  • Cd274 protein, mouse
  • adenomatous polyposis coli protein, mouse